Journal of Muscle Research and Cell Motility

, Volume 35, Issue 1, pp 37–45 | Cite as

Muscle dysfunction in hypertrophic cardiomyopathy: What is needed to move to translation?



Hypertrophic cardiomyopathy (HCM) is caused by mutations in sarcomere genes. As such, HCM provides remarkable opportunities to study how changes to the heart’s molecular motor apparatus may influence cardiac structure and function. Although the genetic basis of HCM is well-described, there is much more limited understanding of the precise consequences of sarcomere mutations—how they remodel the heart, and how these changes lead to the dramatic clinical consequences associated with HCM. More precise characterization of the mechanisms leading from sarcomere mutation to altered cardiac muscle function is critical to gain insight into fundamental disease biology and phenotypic evolution. Such knowledge will help foster development of novel treatment strategies aimed at correcting and preventing disease development in HCM.


Cardiac muscle mechanics Thin filament Thick filament Myofilament calcium sensitivity Excitation contraction coupling Cardiac muscle energetics 



Financial support by Telethon-Italy (Grant No. GGP13162) and the 7th Framework Program of the European Union (‘BIG-HEART’, Grant Agreement 241577) to CP is gratefully acknowledged.

CYH is supported by grants from the National Institutes of Health (1P50HL112349-01, 1UO1 HG006500-01, 1U01HL117006).


  1. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M (2010) Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122:1562–1569PubMedCrossRefGoogle Scholar
  2. Ashrafian H, Watkins H (2007) Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype. J Am Coll Cardiol 49:1251–1264PubMedCrossRefGoogle Scholar
  3. Ashrafian H, Redwood C, Blair E, Watkins H (2003) Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 19:263–268PubMedCrossRefGoogle Scholar
  4. Ashrafian H, Frenneaux MP, Opie LH (2007) Metabolic mechanisms in heart failure. Circulation 116:434–448PubMedCrossRefGoogle Scholar
  5. Baudenbacher F, Schober T, Pinto JR, Sidorov VY, Hilliard F, Solaro RJ, Potter JD, Knollmann BC (2008) Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest 118:3893–3903PubMedCentralPubMedGoogle Scholar
  6. Belus A, Piroddi N, Scellini B, Tesi C, D’Amati G, Girolami F, Yacoub M, Cecchi F, Olivotto I, Poggesi C (2008) The FHC-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J Physiol 586:3639–3644PubMedCentralPubMedGoogle Scholar
  7. Bond LM, Tumbarello DA, Kendrick-Jones J, Buss F (2013) Small-molecule inhibitors of myosin proteins. Future Med Chem 5:41–52PubMedCentralPubMedCrossRefGoogle Scholar
  8. Borbély A, van der Velden J, Bronzwaer JGF, Papp Z, Édes I, Stienen GJM, Paulus WJ (2005) Cardiomyocyte stiffness in diastolic heart failure. Circulation 111:774–781PubMedCrossRefGoogle Scholar
  9. Bottinelli R, Coviello DA, Redwood CS, Pellegrino MA, Maron BJ, Spirito P, Watkins H, Reggiani C (1998) A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res 82:106–115PubMedCrossRefGoogle Scholar
  10. Chandra M, Tschirgi ML, Tardiff JC (2005) Increase in tension-dependent ATP consumption induced by cardiac troponin T mutation. Am J Physiol Heart Circ Physiol 289:H2112–H2119PubMedCrossRefGoogle Scholar
  11. Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F, Sartiani L, Tosi B, Suffredini S, Tesi C, Yacoub M, Olivotto I, Belardinelli L, Poggesi C, Cerbai E, Mugelli A (2013) Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 127:575–584PubMedCrossRefGoogle Scholar
  12. Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K, Watkins H (2003) Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41:1776–1782PubMedCrossRefGoogle Scholar
  13. Cuda G, Fananapazir L, Zhu WS, Sellers JR, Epstein ND (1993) Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J Clin Invest 91:2861–2865PubMedCentralPubMedCrossRefGoogle Scholar
  14. Elliott K, Watkins H, Redwood CS (2000) Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem 275:22069–22077PubMedCrossRefGoogle Scholar
  15. Ferrantini C, Belus A, Piroddi N, Scellini B, Tesi C, Poggesi C (2009) Mechanical and energetic consequences of HCM-causing mutations. J Cardiovasc Transl Res 2:441–451PubMedCrossRefGoogle Scholar
  16. Ferrantini C, Crocini C, Coppini R, Vanzi F, Tesi C, Cerbai E, Poggesi C, Pavone FS, Sacconi L (2013) The transverse-axial tubular system of cardiomyocytes. Cell Mol Life Sci 70:4695–4710PubMedCrossRefGoogle Scholar
  17. Frey N, Brixius K, Schwinger RH, Benis T, Karpowski A, Lorenzen HP, Luedde M, Katus HA, Franz WM (2006) Alterations of tension-dependent ATP utilization in a transgenic rat model of hypertrophic cardiomyopathy. J Biol Chem 281:29575–29582PubMedCrossRefGoogle Scholar
  18. Fujita H, Sugiura S, Momomura S, Omata M, Sugi H, Sutoh K (1997) Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. Molecular force level of mutant myosins may have a prognostic implication. J Clin Invest 99:1010–1015PubMedCentralPubMedCrossRefGoogle Scholar
  19. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG (1990) A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 62:999–1006PubMedCrossRefGoogle Scholar
  20. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124:2761–2796Google Scholar
  21. He H, Javadpour MM, Latif F, Tardiff JC, Ingwall JS (2007) R-92L and R-92W mutations in cardiac troponin T lead to distinct energetic phenotypes in intact mouse hearts. Biophys J 93:1834–1844PubMedCentralPubMedCrossRefGoogle Scholar
  22. He H, Hoyer K, Tao H, Rice R, Jimenez J, Tardiff JC, Ingwall JS (2012) Myosin-driven rescue of contractile reserve and energetics in mouse hearts bearing familial hypertrophic cardiomyopathy-associated mutant troponin T is mutation-specific. J Physiol 590:5371–5388PubMedCentralPubMedCrossRefGoogle Scholar
  23. Hernandez OM, Housmans PR, Potter JD (2001) Pathophysiology of cardiac muscle contraction and relaxation as a result of alterations in thin filament regulation. J Appl Physiol 90:1125–1136PubMedGoogle Scholar
  24. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, Seidman CE, Solomon SD (2002) Assessment of diastolic function with doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 105:2992–2997PubMedCrossRefGoogle Scholar
  25. Ho CY, Carlsen C, Thune JJ, Havndrup O, Bundgaard H, Farrohi F, Rivero J, Cirino AL, Andersen PS, Christiansen M, Maron BJ, Orav EJ, Kober L (2009) Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2:314–321PubMedCentralPubMedCrossRefGoogle Scholar
  26. Ho CY, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, González A, Colan SD, Seidman JG, Díez J, Seidman CE (2010) Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 363:552–563PubMedCentralPubMedCrossRefGoogle Scholar
  27. Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Heydari B, Cirino AL, Lakdawala NK, Orav EJ, González A, López B, Díez J, Jerosch-Herold M, Kwong RY (2013) T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Imaging 6:415–422CrossRefGoogle Scholar
  28. Homsher E, Lee DM, Morris C, Pavlov D, Tobacman LS (2000) Regulation of force and unloaded sliding speed in single thin filaments: effects of regulatory proteins and calcium. J Physiol 524:233–243PubMedCentralPubMedCrossRefGoogle Scholar
  29. Javadpour MM, Tardiff JC, Pinz I, Ingwall JS (2003) Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J Clin Invest 112:768–775PubMedCentralPubMedCrossRefGoogle Scholar
  30. Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O, Bunse M, van Erckelens F, Apitz J, Lutz O, Dietze GJ (1998) 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97:2536–2542PubMedCrossRefGoogle Scholar
  31. Kim JB, Porreca GJ, Song L, Greenway SC, Gorham JM, Church GM, Seidman CE, Seidman JG (2007) Polony multiplex analysis of gene expression (pmage) in mouse hypertrophic cardiomyopathy. Science 316:1481–1484PubMedCrossRefGoogle Scholar
  32. Kraft T, Witjas-Paalberends ER, Boontje NM, Tripathi S, Brandis A, Montag J, Hodgkinson JL, Francino A, Navarro-Lopez F, Brenner B, Stienen GJ, van der Velden J (2013) Familial hypertrophic cardiomyopathy: functional effects of myosin mutation R723G in cardiomyocytes. J Mol Cell Cardiol 57:13–22PubMedCrossRefGoogle Scholar
  33. Lakdawala NK, Thune JJ, Maron BJ, Cirino AL, Havndrup O, Bundgaard H, Christiansen M, Carlsen CM, Dorval JF, Kwong RY, Colan SD, Kober LV, Ho CY (2011) Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol 108:1606–1613PubMedCentralPubMedCrossRefGoogle Scholar
  34. Lankford EB, Epstein ND, Fananapazir L, Sweeney HL (1995) Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest 95:1409–1414PubMedCentralPubMedCrossRefGoogle Scholar
  35. Li Y, Charles PY, Nan C, Pinto JR, Wang Y, Liang J, Wu G, Tian J, Feng HZ, Potter JD, Jin JP, Huang X (2010) Correcting diastolic dysfunction by Ca2+ desensitizing troponin in a transgenic mouse model of restrictive cardiomyopathy. J Mol Cell Cardiol 49:402–411PubMedCrossRefGoogle Scholar
  36. Liu B, Lee RS, Biesiadecki BJ, Tikunova SB, Davis JP (2012) Engineered troponin C constructs correct disease-related cardiac myofilament calcium sensitivity. J Biol Chem 287:20027–20036PubMedCentralPubMedCrossRefGoogle Scholar
  37. Lombardi R, Rodriguez G, Chen SN, Ripplinger CM, Li W, Chen J, Willerson JT, Betocchi S, Wickline SA, Efimov IR, Marian AJ (2009) Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 119:1398–1407PubMedCentralPubMedCrossRefGoogle Scholar
  38. Lowey S (2002) Functional consequences of mutations in the myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. Trends Cardiovasc Med 12:348–354PubMedCrossRefGoogle Scholar
  39. Luedde M, Flögel U, Knorr M, Grundt C, Hippe HJ, Brors B, Frank D, Haselmann U, Antony C, Voelkers M, Schrader J, Most P, Lemmer B, Katus HA, Frey N (2009) Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy. J Mol Med 87:411–422PubMedCrossRefGoogle Scholar
  40. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ (2011) Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331:1439–1443PubMedCrossRefGoogle Scholar
  41. Marian AJ, Roberts R (2001) The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 33:655–670PubMedCentralPubMedCrossRefGoogle Scholar
  42. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the cardia study. Circulation 92:785–789PubMedCrossRefGoogle Scholar
  43. Maron BJ, Seidman JG, Seidman CE (2004) Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 44:2125–2132PubMedCrossRefGoogle Scholar
  44. Marston SB (2011) How do mutations in contractile proteins cause the primary familial cardiomyopathies? J Cardiovasc Transl Res 4:245–255PubMedCrossRefGoogle Scholar
  45. Marston SB, Copeland O, Jacques A, Livesey K, Tsang V, McKenna WJ, Jalilzadeh S, Carballo S, Redwood C, Watkins H (2009) Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 105:219–222PubMedCrossRefGoogle Scholar
  46. Miller G, Maycock J, White E, Peckham M, Calaghan S (2003) Heterologous expression of wild-type and mutant beta-cardiac myosin changes the contractile kinetics of cultured mouse myotubes. J Physiol 548:167–174PubMedCentralPubMedCrossRefGoogle Scholar
  47. Narolska NA, van Loon RB, Boontje NM, Zaremba R, Eiras Penas S, Russell J, Spiegelenberg SR, Huybregts MAJM, Visser FC, de Jong JW, van der Velden J, Stienen GJM (2005) Myocardial contraction is 5-fold more economical in ventricular than in atrial human tissue. Cardiovasc Res 65:221–229PubMedCrossRefGoogle Scholar
  48. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG, Seidman CE (1998) Mutations in the gene for cardiac myosin-binding protein c and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 338:1248–1257PubMedCrossRefGoogle Scholar
  49. Oleszczuk M, Robertson IM, Li MX, Sykes BD (2010) Solution structure of the regulatory domain of human cardiac troponin C in complex with the switch region of cardiac troponin I and W7: the basis of W7 as an inhibitor of cardiac muscle contraction. J Mol Cell Cardiol 48:925–933PubMedCentralPubMedCrossRefGoogle Scholar
  50. Palmer BM, Wang Y, Teekakirikul P, Hinson JT, Fatkin D, Strouse S, Vanburen P, Seidman CE, Seidman JG, Maughan DW (2008) Myofilament mechanical performance is enhanced by R403Q myosin in mouse myocardium independent of sex. Am J Physiol Heart Circ Physiol 294:H1939–H1947PubMedCrossRefGoogle Scholar
  51. Palmiter KA, Tyska MJ, Haeberle JR, Alpert NR, Fananapazir L, Warshaw DM (2000) R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil 21:609–620PubMedCrossRefGoogle Scholar
  52. Piroddi N, Belus A, Scellini B, Tesi C, Giunti G, Cerbai E, Mugelli A, Poggesi C (2007) Tension generation and relaxation in single myofibrils from human atrial and ventricular myocardium. Pflugers Arch 454:63–73PubMedCrossRefGoogle Scholar
  53. Richard P, Villard E, Charron P, Isnard R (2006) The genetic bases of cardiomyopathies. J Am Coll Cardiol 48:A79–A89CrossRefGoogle Scholar
  54. Robertson IM, Li MX, Sykes BD (2009) Solution structure of human cardiac troponin C in complex with the green tea polyphenol, (−)−epigallocatechin 3-gallate. J Biol Chem 284:23012–23023PubMedCentralPubMedCrossRefGoogle Scholar
  55. Roopnarine O, Leinwand LA (1998) Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy. Biophys J 75:3023–3030PubMedCentralPubMedCrossRefGoogle Scholar
  56. Sata M, Ikebe M (1996) Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. J Clin Invest 98:2866–2873PubMedCentralPubMedCrossRefGoogle Scholar
  57. Schober T, Huke S, Venkataraman R, Gryshchenko O, Kryshtal D, Hwang HS, Baudenbacher FJ, Knollmann BC (2012) Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia. Circ Res 111:170–179PubMedCentralPubMedCrossRefGoogle Scholar
  58. Seebohm B, Matinmehr F, Köhler J, Francino A, Navarro-Lopéz F, Perrot A, Ozcelik C, McKenna WJ, Brenner B, Kraft T (2009) Cardiomyopathy mutations reveal variable region of myosin converter as major element of cross-bridge compliance. Biophys J 97:806–824PubMedCentralPubMedCrossRefGoogle Scholar
  59. Seidman JG, Seidman C (2001) The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104:557–567PubMedCrossRefGoogle Scholar
  60. Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, McConnell BK, Reiken S, Mende U, Marks AR, Kass DA, Seidman CE, Seidman JG (2002) The l-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 109:1013–1020PubMedCentralPubMedCrossRefGoogle Scholar
  61. Sequeira V, Wijnker PJ, Nijenkamp LL, Kuster DW, Najafi A, Witjas-Paalberends ER, Regan JA, Boontje N, Ten Cate FJ, Germans T, Carrier L, Sadayappan S, van Slegtenhorst MA, Zaremba R, Foster DB, Murphy AM, Poggesi C, Dos Remedios C, Stienen GJ, Ho CY, Michels M, van der Velden J (2013) Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res 112:1491–1505PubMedCentralPubMedCrossRefGoogle Scholar
  62. Sommese RF, Sung J, Nag S, Sutton S, Deacon JC, Choe E, Leinwand LA, Ruppel K, Spudich JA (2013) Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function. Proc Natl Acad Sci USA 110:12607–12612PubMedCentralPubMedCrossRefGoogle Scholar
  63. Spindler M, Saupe KW, Christe ME, Sweeney HL, Seidman CE, Seidman JG, Ingwall JS (1998) Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest 101:1775–1783PubMedCentralPubMedCrossRefGoogle Scholar
  64. Stelzer JE, Dunning SB, Moss RL (2006) Ablation of cardiac myosin-binding protein-C accelerates stretch activation in murine skinned myocardium. Circ Res 98:1212–1218PubMedCrossRefGoogle Scholar
  65. Sweeney HL, Feng HS, Yang Z, Watkins H (1998) Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc Natl Acad Sci U S A 95:14406–14410PubMedCentralPubMedCrossRefGoogle Scholar
  66. Tyska MJ, Hayes E, Giewat M, Seidman CE, Seidman JG, Warshaw DM (2000) Single molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res 86:737–744PubMedCrossRefGoogle Scholar
  67. Van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JM, Winegrad S, Schlossarek S, Carrier L, ten Cate FJ, Stienen GJ, van der Velden J (2009) Cardiac myosin-binding protein mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 119:1473–1483PubMedCrossRefGoogle Scholar
  68. Witjas-Paalberends ER, Piroddi N, Stam K, van Dijk SJ, Oliviera VS, Ferrara C, Scellini B, Hazebroek M, ten Cate FJ, van Slegtenhorst M, dos Remedios C, Niessen HW, Tesi C, Stienen GJ, Heymans S, Michels M, Poggesi C, van der Velden J (2013) Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc Res 99:432–441PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Department of Experimental and Clinical MedicineUniversity of FlorenceFlorenceItaly
  2. 2.Cardiovascular DivisionBrigham and Women’s HospitalBostonUSA

Personalised recommendations